Filing Details
- Accession Number:
- 0001860010-23-000004
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-09 19:00:15
- Reporting Period:
- 2023-06-09
- Accepted Time:
- 2023-06-09 19:00:15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1711279 | Krystal Biotech Inc. | KRYS | Biological Products, (No Disgnostic Substances) (2836) | 821080209 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1860010 | C. Andrew Orth | C/O Krystal Biotech, Inc. 2100 Wharton Street, Suite 701 Pittsburgh PA 15203 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-06-09 | 12,500 | $63.55 | 12,600 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-06-09 | 5,261 | $128.10 | 7,339 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-06-09 | 6,906 | $128.94 | 433 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-06-09 | 333 | $129.70 | 100 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-06-09 | 12,500 | $0.00 | 12,500 | $63.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 37,500 | 2032-02-27 | No | 4 | M | Direct |
Footnotes
- The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.
- The transaction was executed in multiple trades ranging from $127.5500 to $128.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The transaction was executed in multiple trades ranging from $128.5600 to $129.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The transaction was executed in multiple trades ranging from $129.5600 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- 50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.
Billionaire Hedge Funds
